Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy

Endocrine Journal

Akinobu Nakamura¹  Hideaki Miyoshi¹  Hiroshi Nomoto¹  Hajime Sugawara¹  Kota Ono²  Reina Kameda¹  Mei Ichiyama¹  Kohei Yamamoto¹  Tatsuya Atsumi¹  Chiho Yamamoto¹ 

[1] Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan;Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo 060-8648, Japan

关键词: Diet therapy;    Ipragliflozin;    Visceral adipose tissue;   

DOI  :  10.1507/endocrj.EJ15-0749

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(20)Cited-By(3)To investigate if ipragliflozin, a novel sodium-glucose co-transporter 2 inhibitor, alters body composition and to identify variables associated with reductions in visceral adipose tissue in Japanese patients with type 2 diabetes mellitus.This prospective observational study enrolled Japanese participants with type 2 diabetes mellitus.Subjects were administered ipragliflozin (50 mg/day) once daily for 16 weeks.Body composition, visceral adipose tissue volume and plasma variables were measured at 0, 8, and 16-weeks.The subjects’ lifestyle habits including diet and exercise were evaluated at baseline and 16 weeks.The primary endpoint was defined as the decrease of visceral adipose tissue mass.Twenty-four of 26 enrolled participants completed the study.The visceral adipose tissue decreased significantly (110 ± 33 to 101 ± 36 cm2, p = 0.005) as well as other parameters for metabolic insufficiency including hemoglobin A1c.Seventy-one % of the total body weight reduction (-2.49 kg) was estimated by a decrease in fat mass (-1.77 kg), and the remaining reduction (22%) by water volume (-0.55 kg).A minor but significant reduction in the skeletal muscle index was also observed.Correlation analyses were performed to identify variables associated with changes in visceral adipose tissue and the only significant variable identified was diet therapy (Spearman’s r = -0.416, p = 0.043).Ipragliflozin significantly decreased visceral adipose tissue, and improved parametres for metabolic dysfunction.Adequate diet therapy would be necessary to induce and enhance the therapeutic merit.

【 授权许可】

Unknown